Edition:
United Kingdom

Otsuka Holdings Co Ltd (4578.T)

4578.T on Tokyo Stock Exchange

5,490JPY
21 Sep 2018
Change (% chg)

¥74 (+1.37%)
Prev Close
¥5,416
Open
¥5,448
Day's High
¥5,512
Day's Low
¥5,416
Volume
1,734,300
Avg. Vol
1,103,235
52-wk High
¥5,832
52-wk Low
¥4,421

Latest Key Developments (Source: Significant Developments)

Otsuka Holdings to transfer stake management business to unit Otsuka Medical Devices
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says it will transfer ReCor Medical, Inc related stake management business to unit Otsuka Medical Devices Co Ltd, effective Nov. 1 .  Full Article

DKSH: Otsuka Extends Partnership With DKSH In Hong Kong
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - DKSH Holding AG ::OTSUKA EXTENDS PARTNERSHIP WITH DKSH IN HONG KONG.  Full Article

Otsuka Holdings unit completes acquisition of U.S.-based firm Visterra
Monday, 3 Sep 2018 

Sept 3 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says its unit Otsuka Pharmaceutical Co., Ltd completed acquisition of U.S.-based firm Visterra Inc on Aug. 31 .  Full Article

Astex Pharmaceuticals And Otsuka Announce Results Of The Phase 3 Astral-1 Study Of Guadecitabine In Treatment-Naïve AML Patients Ineligible To Receive Intense Induction Chemotherapy
Monday, 30 Jul 2018 

July 30 (Reuters) - ASTEX PHARMACEUTICALS ::ASTEX PHARMACEUTICALS AND OTSUKA ANNOUNCE RESULTS OF THE PHASE 3 ASTRAL-1 STUDY OF GUADECITABINE (SGI-110) IN TREATMENT-NAÏVE AML PATIENTS INELIGIBLE TO RECEIVE INTENSE INDUCTION CHEMOTHERAPY.ASTEX PHARMACEUTICALS - STUDY DID NOT MEET ITS CO-PRIMARY ENDPOINTS.ASTEX PHARMACEUTICALS SAYS CONTINUES TO FOCUS ON COMPLETING PHASE 3 ASTRAL-2 AND ASTRAL-3 STUDIES.  Full Article

Otsuka Holdings unit to fully acquire U.S.-based firm Visterra via unit for $430 mln
Thursday, 12 Jul 2018 

July 12 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says wholly owned unit Otsuka Pharmaceutical Co., Ltd plans to fully acquire U.S.-based firm Visterra Inc via unit Otsuka America, Inc. in the third quarter for fiscal year 2018.Acquisition price is $430 million.  Full Article

Otsuka Medical Devices, Otsuka Holdings And Recor Medical Announce Signing Of Merger Agreement
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Otsuka Holdings Co Ltd <4578.T>::OTSUKA MEDICAL DEVICES, OTSUKA HOLDINGS AND RECOR MEDICAL ANNOUNCE SIGNING OF MERGER AGREEMENT.MERGER AGREEMENT PURSUANT TO WHICH OTSUKA HOLDINGS WILL ACQUIRE REMAINING SHARES IN RECOR FROM ITS CURRENT HOLDERS.  Full Article

Otsuka Holdings unit and Lundbeck to start third phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with Alzheimer's disease
Thursday, 24 May 2018 

May 24 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says co's unit Otsuka Pharmaceutical Co Ltd and Lundbeck announce that the two companies' third clinical phase 3 study ofbrexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.  Full Article

Otsuka's tolvaptan approved by U.S. FDA as first treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says its unit Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JYNARQUE™ (tolvaptan) as the first drug treatment available to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).  Full Article

Otsuka's JYNARQUE Approved By FDA As First Treatment to Slow Kidney Function Decline
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Otsuka Pharmaceutical::U.S. FDA APPROVED JYNARQUE AS DRUG TREATMENT TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING ADPKD.  Full Article

Otsuka Pharmaceutical Says Co, X-Chem Have Signed Collaborative Research Agreement To Advance Discovery Process For New Otsuka Drug Compounds
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Otsuka Holdings Co Ltd <4578.T>::OTSUKA PHARMACEUTICAL SAYS CO, X-CHEM INC HAVE SIGNED COLLABORATIVE RESEARCH AGREEMENT TO ADVANCE DISCOVERY PROCESS FOR NEW OTSUKA DRUG COMPOUNDS.  Full Article

BRIEF-DKSH: Otsuka Extends Partnership With DKSH In Hong Kong

* OTSUKA EXTENDS PARTNERSHIP WITH DKSH IN HONG KONG Source text - https://bit.ly/2wPf9vb Further company coverage: (Gdynia Newsroom)